CytoDyn announces preliminary findings in study with SMC Laboratories

CytoDyn announced a preliminary review of results from its preclinical study with SMC Laboratories. SMC Laboratories, a company specializing in preclinical drug efficacy evaluations using various models of inflammation and fibrosis in mice, conducted a study that assessed the optimal dosing of leronlimab in the MASH setting and potential synergies with Resmetirom, the only currently approved therapy for the treatment of MASH. A preliminary review of the study results has led to several encouraging findings, as follows: Leronlimab monotherapy demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm; Leronlimab monotherapy appeared to demonstrate dose-dependent antifibrotic activity, with leronlimab 700 mg performing better at reversing liver fibrosis compared to leronlimab 350 mg; and Leronlimab monotherapy appears to have better anti-fibrotic activity compared to Resmetirom.